Perforomist is a brand name of formoterol, approved by the FDA in the following formulation(s):
PERFOROMIST (formoterol fumarate - solution; inhalation)
Manufacturer: DEY PHARMA
Approval date: May 11, 2007
Strength(s): 0.02MG/2ML [RLD]
Has a generic version of Perforomist been approved?
No. There is currently no therapeutically equivalent version of Perforomist available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Perforomist. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Bronchodilating compositions and methods
Patent 6,667,344
Issued: December 23, 2003
Inventor(s): Partha S.; Banerjee & Stephen; Pham & Samuel O.; Akapo & Imtiaz A.; Chaudry
Assignee(s): Dey, L.P.
Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.Patent expiration dates:
- June 22, 2021✓
- June 22, 2021
Bronchodilating compositions and methods
Patent 6,814,953
Issued: November 9, 2004
Inventor(s): Partha S.; Banerjee & Stephen; Pham & Samuel O.; Akapo & Imtiaz A.; Chaudry
Assignee(s): Dey L.P.
Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.Patent expiration dates:
- June 22, 2021✓✓
- June 22, 2021
Bronchodilating β-agonist compositions and methods
Patent 7,348,362
Issued: March 25, 2008
Inventor(s): Banerjee; Partha S. & Chaudry; Imtiaz A. & Pham; Stephen
Assignee(s): Dey, L.P.
Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.Patent expiration dates:
- June 22, 2021✓
- June 22, 2021
Bronchodilating beta-agonist compositions and methods
Patent 7,462,645
Issued: December 9, 2008
Inventor(s): Chaudry; Imtiaz A. & Pham; Stephen & Banerjee; Partha S.
Assignee(s): JPMorgan Chase Bank, N.A.
Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.Patent expiration dates:
- June 22, 2021✓✓
- June 22, 2021
See also...
- Perforomist Consumer Information (Drugs.com)
- Perforomist Solution Consumer Information (Wolters Kluwer)
- Perforomist Consumer Information (Cerner Multum)
- Perforomist Advanced Consumer Information (Micromedex)
- Formoterol Consumer Information (Wolters Kluwer)
- Formoterol Solution Consumer Information (Wolters Kluwer)
- Formoterol Consumer Information (Cerner Multum)
- Formoterol Inhalation, oral/nebulization Advanced Consumer Information (Micromedex)
- Formoterol Fumarate AHFS DI Monographs (ASHP)
No comments:
Post a Comment